COMPASS Pathways Plc Sponsored ADR CMPS 深 滬
等待開盤 06-25 09:30:00 美东时间
12.58
-0.070
-0.55%
華盛通- 最 高13.50
- 今 開12.74
- 成交量 409.86万股
- 最 低 12.34
- 昨 收 12.65
- 總市值 169.77万
- 52周最高 14.76
- 市盈率 靜 --
- 換手率 3.04%
- 52周最低 3.24
- 委 比 -94.63%
- 總股本 0.00亿
- 歷史最高 61.69
- 量 比 1.53
- 振 幅 9.17%
- 歷史最低 2.25
- 每 手 1
- 風險率 2.36%
個股概要
財務分析
公司資料
相關新聞
分紅派息
- 分時圖
- 日k
- 周k
- 月k
相關新聞
更多UPDATE 2-Definium's LSD-based depression pill delivers strong late-stage results, shares surge
UPDATE 2-Definium's LSD-based depression pill delivers strong late-stage results, shares surge Updates share movement, adds analyst comment 6 and 7, background throughout By Kamal Choudhury June 22 (Reuters) - Definium Therapeutics DFTX.O said a single dose of its LSD-based experimental pill signifi
06-22 19:11
Compass Pathways为17名新员工授予股权激励 加快商业团队扩张
临床阶段生物技术公司Compass Pathways周五宣布，根据纳斯达克上市规则第5635（c）（4）条，向17名新聘非执行员工授予股权激励奖励。这是该公...
06-05 21:53
Trump's psychedelic drug order boosts investor interest with promise of faster reviews
Trump's psychedelic drug order boosts investor interest with promise of faster reviews By Kamal Choudhury and Christy Santhosh May 18 (Reuters) - U.S. President Donald Trump's executive order to accelerate psychedelic drug development has raised hopes among companies developing the drugs that it cou
05-18 18:00
Why LiveRamp Shares Are Trading Higher By Over 26%; Here Are 20 Stocks Moving Premarket
Liveramp Holdings Inc (NYSE: RAMP) rose in pre-market trading after being acquired by Publicis for $2.2 billion. Other gainers include SBFM, NXXT, GOVX, CREG, PMI, ZDAI, GCTS, CMPS, and DXYZ. BTM, EDBL, PIII, ARTL, and HCWB were among the losers.
05-18 17:38
美股大行评级 | 应用材料获17家大行集体上调目标价；Bitdeer 、Forgent 、嘉信理财、Viking等获多家大行上调目标价
今日重点评级关注：Chardan Capital：维持Senti Biosciences"买入"评级，目标价从11美元升至12美元；Ladenburg Thalmann：维持Usio"买入"评级，目标价从5.75美元升至6.25美元
05-18 11:48
美股大行评级 | 阿里、京东、英伟达、思科等获多家大行上调目标价；Doximity、Dynatrace、Enovix、Wix.com等遭多家大行下调目标价
今日重点评级关注：HC Wainwright & Co.：维持Autolus Therapeutics"买入"评级，目标价从9美元升至10美元；Maxim Group：维持Rezolute"买入"评级，目标价从4美元升至10美元
05-15 10:49
Morgan Stanley Maintains Overweight on Compass Pathways, Raises Price Target to $17
Morgan Stanley analyst Judah Frommer maintains Compass Pathways (NASDAQ:CMPS) with a Overweight and raises the price target from $16 to $17.
05-15 00:44
RBC Capital Maintains Outperform on Compass Pathways, Raises Price Target to $22
RBC Capital analyst Leonid Timashev maintains Compass Pathways (NASDAQ:CMPS) with a Outperform and raises the price target from $21 to $22.
05-15 00:40
美股夜盘 | 思科涨20.68%，StubHub Holdings Incorporation Class A涨12.10%
思科涨20.68%；StubHub Holdings Incorporation Class A涨12.10%；WhiteFiber涨8.66%
05-14 10:01
